kodak &lt;ek> buys stake enzon &lt;enzn> eastman kodak acquired 18.7 pct equity interest enzon inc, pharmaceutical company specializing protein therapy. kodak secured worldwide marketing rights enzon's peg enzymes treatment oxygen toxicity disorders, hyperuricemia gout. company acquired mln enzon shares 15 mln dlrs, loans enzon mln dlrs interest 30,000 dlrs credited purchase price. kodak drugs covered marketing rights initial stages u.s. food drug administration approval process. investment provide capital complete fda review process provide marketing outlet drugs. drugs peg-superoxide disdmutase peg-catalase, oxygen toxicity disorders often-fatal tissue damage severe burns, organ transplants, heart attacks trauma, peg-uricase, treatment gout conditions caused buildup high levels uric acid body.